Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its lead product is ITIL-306, a Co-Stimulatory Antigen Receptor molecule to recognize folate receptor alpha, a tumor-associated antigen that is expressed on various solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Stock data | 2024 | Change |
---|---|---|
Price | $66.10 | N/A |
Market Cap | $429.91M | N/A |
Shares Outstanding | 6.50M | N/A |
Employees | 192.00 | N/A |